Highlights of This Issue 6645

SPECIAL FEATURES

CCR Translations

6647

The Context of Blood Vessels and Response to VEGF-Targeted Therapy
Brian I. Rini
See related article, p. 6943

HUMAN CANCER BIOLOGY

6650

Abiraterone Acetate in Combination withPrednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

6657

Pralatrexate Pharmacology and Clinical Development
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O’Connor

Molecular Pathways

6662

Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
Lorena Fontán and Ari Melnick

Perspectives

6669

Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?
Anita Sveen, Arild Neskabken, Trude H. Aagesen, Marianne G. Gurein, Kjell M. Tveit, Børre L. Skotheim, and Ragnhild A. Lothe

Review

6678

Hepatocellular Carcinoma from an Immunologic Perspective
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

6686

Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Bute Alvarez, Maria Gomes da Silva, José Cabeças, Maria Calaminici, and John G. Gribben

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

6696

HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Ling Li, Wenhua Tang, Xiaoqing Wu, David Karnak, Xiaojie Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jianyun Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

CANCER THERAPY: PRECLINICAL

6716

Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagyembek Manap, Lirin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Klein, Werner Scheuer, Romi Raemisch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarelo, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas

Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response

Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milosevic, Bradly G. Wouters, Robert G. Bristow, and Marianne Koritzinsky

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loreta Pia Ciaffreda, Sara Costantino, Floraiana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D’Aiuto, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello

IMAGING, DIAGNOSIS, PROGNOSIS

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma


A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

Isabel Puig, Irene Chicote, Stephen P. Tenbaum, Oriol Arqués, José Raúl Herance, Juan D. Gispert, José Jimenez, Stefania Landolfi, Karina Caci, Helena Allende, Leire Mendizabal, Debora Moreno, Ramón Charco, Eloy Espín, Alex Prat, Maria Elena Elez, Guillem Argilés, Ana Vivancos, Josep Tabernero, Santiago Rojas, and Héctor G. Palmer

Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis

Ren Liu, Xiaqing Li, Wenming Guo, Yue Zhou, Shuang Wei, Satyajit K. Mitra, Valery Krasnoperov, Dezhong Dong, Shuanglong Liu, Dan Li, Genyuuan Zhu, Stan Louie, Peter S. Conti, ZiBo Li, Amy S. Lee, and Parkash S. Gill

Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors

Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock

A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma

Arutselvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas


Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy
Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao

CANCER THERAPY: CLINICAL

Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis
Carlo Palmieri, John R. Fullarton, and Janet Brown

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Steter-Stevenson

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jie Xin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes

Long-term Survival and Biomarker Correlates of TASquinomod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors
David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Haverty, Bianca Liederer, Xiaorong Liang, Robert L. Yauch, Thomas O’Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanjiang Cui, Xian Sheng, Lili Mao, Siming Li, Bin Lian, Rui Feng Yang, Shujing Liu, Xiaowei Xu, and Jun Guo

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
See related article, p. 6647

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials in Oncology
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan, Violeta Serra, Ludmilta Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, and José Baselga

Acknowledgment to Reviewers

ABOUT THE COVER

The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.